Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Exploratory Phase 2 a Study to Assess Safety, Tolerability, Pharmacodynamic and Pharmacokinetics of VAS203 in Patients With Moderate and Severe Traumatic Brain Injury

Next Previous
X
Search
Trial Profile

An Exploratory Phase 2 a Study to Assess Safety, Tolerability, Pharmacodynamic and Pharmacokinetics of VAS203 in Patients With Moderate and Severe Traumatic Brain Injury

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ronopterin (Primary)
  • Indications Traumatic brain injuries
  • Focus Adverse reactions
  • Acronyms NOSTRA; NOSTRA II
  • Sponsors vasopharm BIOTECH

    • Most Recent Events

    • 12 Jul 2022 Results of post hoc analyses of clinical trials (NOSTRA and NOSTRA-III), published in the vasopharm BIOTECH Media Release.
    • 10 May 2022 Results published in the vasopharm BIOTECH Media Release.
    • 08 Feb 2022 Post-hoc analysis from the pooled data of NOSTRA and NOSTRA III studies presented in a Vasopharm media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top